Target Trial Emulation Finds Limited Survival Benefit With Statins After Colorectal Cancer Treatment

Statins may offer little survival benefit when initiated after colorectal cancer (CRC) treatment, according to findings from a nationwide cohort study published in JAMA Network Open. Although statin initiation was associated with slightly lower CRC-specific mortality, the absolute difference in 5-year CRC-specific survival was small and not statistically significant.¹

The findings challenge earlier observational studies that suggested substantial survival advantages with statin use after a cancer diagnosis. According to the investigators, some of those associations may have resulted from study-design issues rather than an anticancer effect.

Researchers Emulate a Randomized Trial

Statins are widely prescribed to reduce cardiovascular risk. Laboratory findings indicating that these agents may have anti-inflammatory and antiproliferative effects have also raised interest in repurposing them as adjunctive cancer treatments.² Previous observational research has linked postdiagnosis statin use with improved survival among patients with colon cancer.³

However, medication studies conducted after a cancer diagnosis are vulnerable to immortal time bias. This occurs when patients categorized as receiving a treatment must remain alive long enough to start it, creating an artificial survival advantage for the treated group. This includes patients who already tolerate a medication and selectively censoring participants when treatment changes can further distort results.⁴

To address these problems, investigators used target trial emulation, a framework designed to approximate the protocol of a randomized clinical trial using observational data. The analysis included 88,516 adults newly diagnosed with CRC in South Korea between 2005 and 2015. None had received a statin prescription during the 6 months prior to diagnosis.

The date of the patients’ first CRC treatment served as time zero. Investigators compared initiation of any statin within the following 6 months with no initiation during that period. A clone-censor weight method and stabilized inverse probability of censoring weights were used to account for deviations from the assigned treatment strategies and time-varying confounding. Patients were followed for up to 60 months.¹

Absolute Survival Differences Remained Small

Only 2071 patients (2.3%) of the total cohort initiated statin therapy within 6 months of CRC treatment, and he remaining 86,445 patients did not. After adjustment, statin initiation was associated with a modest reduction in CRC-specific mortality compared with noninitiation (HR, 0.95; 95% CI, 0.92-0.99). The association with all-cause mortality did not reach statistical significance (HR, 0.96; 95% CI, 0.93-1.00).¹

The absolute findings offered important context. At 60 months, the standardized difference in CRC-specific survival between hypothetical universal statin initiation and universal noninitiation was about 1.1 percentage points (95% CI, –0.1 to 2.3). Because the confidence interval included zero, the difference was not statistically significant. The corresponding difference in all-cause survival was 2.4 percentage points (95% CI, 1.0-3.8).¹

When investigators deliberately used conventional analytical approaches that introduced immortal time bias, statins appeared far more protective. In one analysis, statin use was associated with an 83% reduction in CRC-specific mortality (adjusted HR, 0.17; 95% CI, 0.16-0.17). Including prevalent users also produced stronger associations than the target trial emulation.

The contrast illustrates how methodological choices can transform a small association into an apparently substantial treatment effect.

Findings Do Not Support Statins as CRC Therapy

The study does not change the established cardiovascular indications for statin therapy. Patients with CRC may still require statins for primary or secondary cardiovascular prevention based on their individual risk factors. Instead, the findings suggest that health care professionals should not interpret statin initiation as an evidence-based strategy for improving CRC survival.

The authors acknowledged several limitations. Cancer stage was unavailable in the claims database and was approximated through treatment patterns. The analysis evaluated statins as a class, although individual agents could have different biological effects. Only a small proportion of patients initiated therapy, limiting the evaluation of differences across disease-severity groups. The 6-month washout period may also have classified some former statin users as new users.¹

For oncology pharmacists, the results reinforce the need to distinguish cardiovascular medication management from unproven cancer-directed repurposing. They also demonstrate why absolute survival differences and study design deserve attention alongside relative measures such as hazard ratios. Based on these findings, statin use after CRC treatment should remain guided by cardiovascular indications rather than an expectation of a meaningful anticancer survival benefit.

REFERENCES

1. Woo H, Shin A. Statin Initiation and Mortality After Colorectal Cancer Treatment. JAMA Netw Open.2026;9(9):e2633680. doi:10.1001/jamanetworkopen.2026.33680

2. Kodach LL, Jacobs RJ, Voorneveld PW, et al. Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell 'stemness' via the bone morphogenetic protein pathway. Gut. 2011;60(11):1544-1553. doi:10.1136/gut.2011.237495

3. Voorneveld PW, Reimers MS, Bastiaannet E, et al. Statin Use After Diagnosis of Colon Cancer and Patient Survival. Gastroenterology. 2017;153(2):470-479.e4. doi:10.1053/j.gastro.2017.05.011

4. Hernán MA, Sauer BC, Hernández-Díaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol. 2016;79:70-75. doi:10.1016/j.jclinepi.2016.04.014